Vargas-Hernández VM, Acosta-Altamirano G, Moreno-Eutimio MA, Vargas-Aguilar VM, Flores-Barrios K, Tovar-Rodríguez JM

Idioma: Español
Referencias bibliográficas: 31
Paginas: 251-261
Archivo PDF: 223.70 Kb.

RESUMEN

La menopausia se caracteriza por amenorrea durante un año, debido a la suspensión de la función ovárica. La esperanza de vida de las mujeres ahora es mayor a partir de ésta, por lo que es necesario garantizar la calidad de vida; la terapia hormonal contribuye en gran medida al bienestar de la salud de estas mujeres. El tratamiento hormonal durante la menopausia ha cambiado de manera significativa a partir de 2002. Los estudios actuales sugieren el tratamiento individual con dosis baja de estrógeno y utilizarse el menor tiempo posible, pero implican riesgos que deben ser informados para determinar si los beneficios son mayores; la terapia hormonal es aceptable y segura en mujeres sanas al final de la quinta década de la vida o dentro de los primeros 10 años de iniciar la menopausia. El manejo hormonal debe ser individualizado sobre riesgos y beneficios basados en las nuevas recomendaciones basadas en evidencias para su uso, que pueden modificarse con el tiempo.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Geukes M, van Aalst MP, Nauta MC, Oosterhof H. The impact of menopausal symptoms on work ability. Menopause 2012; 19: 278-82.

2. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al, for the STRAW + 10 Collaborative Group. Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging. Menopause 2012; 19: 387-95.

3. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2012; 19: 257-71.

4. Ayers B, Hunter MS. Health-related quality of life of women with menopausal hot flushes and night sweats. Climacteric 2013; 16: 235-9.

5. Santoro N, Randolph JF Jr. Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am 2011; 38(3): 455-66.

6. Crandall CJ, Tseng CH, Crawford SL, Thurston RC, Gold EB, Johnston JM, et al. Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition. J Bone Miner Res 2011; 26: 840-9.

7. Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clin Proc 2011; 86(7): 673-80.

8. Panay N, Hamoda H, Arya R, Savvas M. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int 2013; 19(2): 59-68.

9. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011; 16(4): 424-31.

10. Hansen KA, Eyster KM. What Happened to WHI: Menopausal Hormonal Therapy in 2012. Clin Obstet Gynecol 2012; 55(3): 706-12.

11. Griesser H, Skonietzki S, Fischer T, Fielder K, Suesskind M. Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 2012; 71: 360-8.

12. North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013; 20(9): 888-902.

13. Rossouw JE, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women’s Health Initiative trials of menopausal hormone therapy. Obstet Gynecol 2013; 121(1): 172-6.

14. Gass M, Cochrane BB, Larson JC, Manson JE, Barnabei VM, Brzyski RG, et al. Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women’s Health Initiative. Menopause 2011; 18: 1160-71.

15. Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause 2011; 18: 962-6.

16. Davies E, Mangongi NP, Carter CL. Is timing everything? A meeting report of the Society for Women’s Health Research roundtable on menopausal hormone therapy. J Womens Health 2013; 22(4): 303-11.

17. Christenson ES, Jiang X, Kagan R, Schnatz P. Osteoporosis management in post-menopausal women. Minerva Ginecol 2012; 64(3): 181-94.

18. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al., for the WHI Investigators. Health outcomes Rev Hosp Jua Mex 2013; 80(4): 251-261 Vargas-Hernández VM y cols. Terapia hormonal de reemplazo durante la menopausia. 261 after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305(13): 1305-14.

19. Jacoby VL, Grady D, Wactawski-Wende J, Manson JE, Allison MA, Kuppermann M, et al. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women’s Health Initiative Observational Study. Arch Intern Med 2011; 171(8): 760-8.

20. Cortet B, Thomas T, Audran M, Blain H, Breuil V, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 2012; 79(3): 304-13.

21. Stuenkel CA, Gass ML, Manson JE, Lobo RA, Pal L, Rebar RW, et al. A decade after the Women’s Health Initiative - the experts do agree. Menopause 2012; 19(7): 836-7.

22. Lisabeth L, Bushnell C. Stroke risk in women: the role of menopause and hormone therapy. Lancet Neurol 2012; 11: 82-91.

23. Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011; 17: 1052-9.

24. Canonico M, Plu-Bureau G, Scarabin PY. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas 2011; 70: 354-60.

25. Chlebowski RT, Anderson GL. Menopausal Hormone Therapy and Breast Cancer. J Natl Cancer Inst 2012; 104(7): 517-27.

26. Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. Hormone replacement therapy and breast cancer: heterogenous risks by race, weight, and breast density. J Natl Cancer Inst 2013; 105(18): 1365-72.

27. Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 2010; 28: 1540-6.

28. Palacios S. Terapia de reemplazo hormonal y cáncer. En: Vargas-Hernández VM (ed.). Cáncer en la mujer. México: Alfil; 2011, p. 1397-404.

29. Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, et al Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women. A Randomized Controlled Trial. JAMA 2011; 305(3): 267-74.

30. Rogines-Velo MP, Heberle AE, Joffe H. Effect of medroxyprogesterone on depressive symptoms in depressed and nondepressed perimenopausal and postmenopausal women after discontinuation of transdermal estradiol therapy. Menopausia 2012; 19: 471-5.

31. Stephenson K, Neuenschwander PF, Kurdowska AK. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women. Int J Pharm Compd 2013; 17: 74-85.